Skip to main content
Premium Trial:

Request an Annual Quote

Ariadne Genomics, NextGen Sciences, Amersham Biosciences, Target Discovery, PerkinElmer

Premium

Ariadne Genomics announced last week the release of its PathwayAssist 2.0 software for the visualization and analysis of cell signaling pathways, molecular networks, and protein-protein interaction data. The software comes with MedScan for automated extraction of information from scientific literature, and ResNet, a molecular networks database compiled from Medline abstracts.


NextGen Sciences announced last week at the Proteome Forum in Munich the European launch of the a2DETM, an automated 2D gel system, and the expressionfactory, a platform for automated, high throughput protein expression and purification that the company says can produce in parallel hundreds of purified proteins.


Amersham Biosciences announced this week the launch of three new Biotrak ELISAs for detecting markers of neurodegenerative diseases. The ELISAs detect three markers — beta amyloid 1-40, beta amyloid 1-42, and synuclein — which are all implicated in Alzheimer's and Parkinson's disease.


Target Discovery announced at the UBS Global Life Sciences Conference this week the launch of its EOTrol line of coating reagents for electrophoretic separations. The products improve reproducibility in capillary and microchannel electrophoretic separations and allows for a wider range of anion and cation separations than is otherwise available for full-proteome level work, according to the company.


PerkinElmer announced this week that it is launching seven new biomolecular screening products for high-throughput screening and liquid handling at the Society for Biomolecular Screening conference in Portland, Ore.

Highlights of the launch include FlashBlue GPCR beads for receptor-ligand binding applications, LumiTrak Luminescence Cellular and Scintillation Imaging System for fiber-optic imaging, ATPlite OneStep, MultiPROBE II PLUS, and FlexDrop.

 

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.